Clinical Trial

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-09.
Status change: Not Yet Recruiting → Recruiting 2024-09-09
Trial Details
NCT Number NCT06079112
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Advanced Urothelial Carcinoma
Enrollment 100 participants
Start Date 2023-09-27
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19